ALPN - Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse

2024-04-12 05:08:54 ET

Summary

• Vertex Pharmaceuticals is the world's only provider of gene-based therapy for cystic fibrosis, with a $10 billion revenue business.
• The acquisition of Alpine Immune Sciences adds another therapy to Vertex's pipeline, potentially increasing the company's value.
• There is a good opportunity for Vertex and Alpine's individual expertise to benefit each other, making them stronger together.

Investment Thesis

Vertex Pharmaceuticals ( VRTX ) is the world’s only provider of a gene-based therapy for cystic fibrosis and has built a $10bn revenue business around it by continually adding regulatory and funding approvals for more age groups in more geographies. Vertex Also has a pipeline of new therapies which, whilst still some distance from commercialization, continue to progress.1...

For further details see: